In conclusion, combining ebselen oxide with anti‐HER2 agents, lapatinib or trastuzumab, could provide a strong benefit as these combined treatments reached greater efficacy than treatment with single molecules to block HER2 signaling in HER2‐positive cancer cells and would thus allow the use of sub‐optimal doses and subsequent reduction of toxicity‐related adverse effects. The gene discussed is ERBB2; the disease is cancer.